Triall-pris (TRL)

What is Triall (TRL)? Triall is a digital ecosystem of blockchain-enabled software solutions for clinical trials.

The project leverages blockchain and related technologies to make clinical trial processes tamper-resistant, and to enable secure and compliant connections between the many isolated systems and parties involved in clinical research.

Triall was founded back in 2018 and has since developed and commercialized its first product Verial eTMF, a blockchain-integrated document management application that enables clinical researchers to generate verifiable proofs of the existence, integrity, and authenticity of essential clinical trial documents.

Next to Verial eTMF, Triall will release several complementary, industry-validated applications that are all designed to support clinical trial professionals in their day-to-day operations. Moreover, the project is offering APIs that enable existing third-party clinical trial software providers to connect to Triall’s blockchain infrastructure. This provides them and their users a gateway to blockchain functionalities, and enables secure and compliant integrations with other applications in the Triall ecosystem.

Triall’s native TRL token enables access to ecosystem utilities, P2P compensation, governance, and community engagement.

The project is on a mission to accelerate the introduction of safe and affordable new vaccines and therapeutics into society by streamlining clinical trial operations.

Who are the founders of TRL? Triall was founded by a group of clinical operations experts, enterprise IT specialists, and blockchain developers.

Combined, their team has managed 100+ clinical trials, co-founded 20+ business ventures, and published 250+ peer-reviewed papers on innovation in medical research. This experience has left Triall with an extensive network within clinical research and the Life Sciences at large.

Over the past 3 years, Triall has built an international network of partners and a global advisory board consisting of industry experts and Key Opinion Leaders that support the project in the buildout of its blockchain-enabled ecosystem.

What makes Triall unique? As frontrunner in the clinical trials industry, Triall applies blockchain technology to address two industry-wide needs: (1) promoting traceability and auditability of clinical trial operations, which have become increasingly complex and data-heavy; and (2) enabling secure and compliant transfer of clinical trial data between organizations and systems, thereby promoting interoperability and tackling the growing problem of data fragmentation.

Triall takes an ‘ecosystem approach’ that is unique to the clinical trials industry: by enabling secure and compliant integrations between currently isolated clinical trial software, the project aims to turn current competitors into cooperators for the benefit of faster and more-efficient clinical trials. To this end, the project leverages emerging open blockchain standards such as Decentralized Identifiers (DIDs) and Verifiable Credentials (VCs). These will shape a decentralized identity and access management infrastructure for connecting systems and their users in a secure environment.